Ownership Submission
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
OMB APPROVAL
|
OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5
|
|
1. Name and Address of Reporting Person *
|
Nelson Jennifer Ann
|
|
2. Date of Event Requiring Statement (Month/Day/Year)
2024-11-22
|
3. Issuer Name and Ticker or Trading Symbol
Omega Therapeutics, Inc. [OMGA]
|
(Last)
|
(First)
|
(Middle)
|
C/O OMEGA THERAPEUTICS, INC. , 140 FIRST STREET, SUITE 501
|
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
|
_____ 10% Owner
|
_____ Officer (give title below)
|
_____ Other (specify below)
|
Chief Scientific Officer /
|
|
5. If Amendment, Date Original Filed (Month/Day/Year)
|
(Street)
|
CAMBRIDGE
|
MA
|
02141
|
|
6. Individual or Join/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
|
Table I - Non-Derivative Securities Beneficially Owned
|
|
1.Title of Security
|
2. Amount of Securities Beneficially Owned
|
3. Ownership Form: Direct (D) or Indirect (I)
|
4. Nature of Indirect Beneficial Ownership
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
|
2. Date Exercisable and Expiration Date
|
3. Title and Amount of Securities Underlying Derivative Security
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
|
6. Nature of Indirect Beneficial Ownership
|
Date Exercisable
|
Expriation Date
|
Title
|
Amount or Number of Shares
|
Reporting Owners
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Nelson Jennifer Ann
C/O OMEGA THERAPEUTICS, INC.
140 FIRST STREET, SUITE 501
CAMBRIDGE, MA02141
|
|
|
Chief Scientific Officer
|
|
Signatures
/s/ Jennifer A. Nelson
|
2024-11-26
|
**Signature of Reporting Person
|
Date
|
Explanation of Responses:
(*)
|
If the form is filed by more than one reporting person, see Instruction 5(b)(v).
|
(**)
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
(1)
|
The option vests and becomes exercisable with respect to 25% of the underlying shares on August 14, 2025 and in 12 equal quarterly installments thereafter such that the option will become fully vested and exercisable on August 14, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
|
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.